Economy/Home · Economy

Kangstem Biotech to Receive 3 Billion Won in Second Milestone Payment for Knee Osteoarthritis Treatment (OSCA), to Be Paid in Installments of 1 Billion Won

Kangstem Biotech announced in a regulatory filing on the 17th that it is set to receive 3 billion won in milestone payments under the license agreement for its knee osteoarthritis treatment 'OSCA.' The payment is the second milestone payment under the terms of the license agreement signed with Yuya

Oseong Kwon
Staff Reporter
3 min read
Kangstem Biotech to Receive 3 Billion Won in Second Milestone Payment for Knee Osteoarthritis Treatment (OSCA), to Be Paid in Installments of 1 Billion Won
CBC News

Kangstem Biotech announced in a regulatory filing on the 17th that it is set to receive 3 billion won in milestone payments under the license agreement for its knee osteoarthritis treatment 'OSCA.'

The payment is the second milestone payment under the terms of the license agreement signed with Yuyang Pharmaceutical on November 7, 2024. Under the contract, the payment condition is the earlier of 'the selection of a domestic co-development partner' or 'the end of 2026.' Kangstem Biotech stated that it received written notice from Yuyang Pharmaceutical on the same day that the payment condition had been met.

In terms of scale, the expected 3 billion won payment equals 10% or more of the company's consolidated revenue for the most recent fiscal year (3,572,463,936 won).

The payment will be made in installments of 1 billion won each. The company plans to issue the first invoice in the month it receives written notice of the condition's fulfillment, and issue tax invoices in 1-billion-won increments based on that. Each installment is due by the end of the month following the issuance date of the corresponding invoice.

Additionally, Kangstem Biotech explained that it has no obligation to return the milestone payments received, even in the event of mid-term termination of the contract or under any other circumstances.

Meanwhile, the technology covered by this agreement includes patents transferred from the Seoul National University Industry-Academic Cooperation Foundation. Accordingly, a certain portion of the technology fees received under the license agreement related to that technology will be distributed according to contract terms agreed upon with the foundation.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.